Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD)
NCT04087915
·
clinicaltrials.gov ↗
UNKNOWN
Status
1000
Enrollment
OTHER
Sponsor class
Conditions
Dyslipidemia
High Risk Coronary Artery Disease
Interventions
DRUG:
Evolocumab
Sponsor
Beijing Anzhen Hospital